Display options
Cite
Eguchi Y, Gando S, Ishikura H, et al. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intensive Care. 2014;2(1):30doi: 10.1186/2052-0492-2-30.
Eguchi, Y., Gando, S., Ishikura, H., Saitoh, D., Mimuro, J., Takahashi, H., Kitajima, I., Tsuji, H., Matsushita, T., Tsujita, R., Nagao, O., & Sakata, Y. (2014). Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. Journal of intensive care, 2(1), 30. https://doi.org/10.1186/2052-0492-2-30
Eguchi, Yutaka, et al. "Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation." Journal of intensive care vol. 2,1 (2014): 30. doi: https://doi.org/10.1186/2052-0492-2-30
Eguchi Y, Gando S, Ishikura H, Saitoh D, Mimuro J, Takahashi H, Kitajima I, Tsuji H, Matsushita T, Tsujita R, Nagao O, Sakata Y. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intensive Care. 2014 Apr 30;2(1):30. doi: 10.1186/2052-0492-2-30. eCollection 2014. PMID: 25520842; PMCID: PMC4267702.
Copy Download .nbib Format: NLM
Share it on

J Intensive Care. 2014 Apr 30;2(1):30. doi: 10.1186/2052-0492-2-30. eCollection 2014.

Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation.

Journal of intensive care

Yutaka Eguchi, Satoshi Gando, Hiroyasu Ishikura, Daizoh Saitoh, Jun Mimuro, Hoyu Takahashi, Isao Kitajima, Hajime Tsuji, Tadashi Matsushita, Ryuichi Tsujita, Osamu Nagao, Yoichi Sakata

Affiliations

  1. Department of Critical and Intensive Care Medicine, Shiga University of Medical Science, Shiga, Japan ; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin® Injection, Tokyo, Japan.
  2. Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
  3. Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
  4. Division of Traumatology, National Defense Medical College Research Institute, National Defense Medical College, Saitama, Japan.
  5. Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University, School of Medicine, Tochigi, Japan ; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin® Injection, Tokyo, Japan.
  6. Department of Internal Medicine, Niigata Prefectural Kamo Hospital, Niigata, Japan ; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin® Injection, Tokyo, Japan.
  7. Department of Clinical Laboratory and Molecular Pathology, Graduate School of Medical and Pharmaceutical Science, University of Toyama, Toyama, Japan ; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin® Injection, Tokyo, Japan.
  8. Department of Blood Transfusion, Kyoto Prefectural University of Medicine, Kyoto, Japan ; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin® Injection, Tokyo, Japan.
  9. Department of Transfusion Medicine, Nagoya University Hospital, Aichi, Japan ; The Japanese Society on Thrombosis and Hemostasis Post-Marketing Surveillance Committee for Recomodulin® Injection, Tokyo, Japan.
  10. ART Project, Pharmaceuticals Sales Division, Asahi Kasei Pharma Corporation, Tokyo, Japan.
  11. Post-Marketing Surveillance Dept. Reliability Assurance Center, Asahi Kasei Pharma Corporation, Tokyo, Japan.

PMID: 25520842 PMCID: PMC4267702 DOI: 10.1186/2052-0492-2-30

Abstract

BACKGROUND: Thrombomodulin alfa (TM-α, recombinant thrombomodulin) significantly improved disseminated intravascular coagulation (DIC) when compared with heparin therapy in a phase III study. Post-marketing surveillance of TM-α was performed to evaluate the effects and safety in patients with sepsis-induced DIC.

METHODS: From May 2008 to April 2010, a total of 1,787 patients with sepsis-induced DIC treated with TM-α were registered. DIC was diagnosed based on the Japanese Association for Acute Medicine (JAAM) criteria. The DIC resolution and survival rates on day 28 after the last TM-α administration, and changes in DIC, systemic inflammatory response syndrome (SIRS), and sequential organ failure assessment (SOFA) scores and coagulation and inflammation markers were evaluated.

RESULTS: The most frequent underlying disease was infectious focus-unknown sepsis (29.8%). The mean ± SD values of age, dose, and the duration of TM-α administration were 64.7 ± 20.3 years, 297.3 ± 111.4 U/kg/day, and 5.6 ± 3.4 days, respectively. A total of 1,320 subjects (73.9%) received combined administration with other anticoagulants. Both coagulation and inflammation markers, such as fibrin/fibrinogen degradation products, prothrombin time ratio, thrombin-antithrombin complex, and C-reactive protein, as well as JAAM DIC, SIRS, and SOFA scores, significantly and simultaneously decreased after TM-α administration (p < 0.001). DIC resolution and 28-day survival rates were 44.4% and 66.0%, respectively. The 28-day survival rate decreased significantly according to the duration of DIC before TM-α administration (p < 0.001). Total adverse drug reactions (ADRs), bleeding ADRs, and serious bleeding adverse events occurred in 126 (7.1%), 98 (5.5%), and 121 (6.8%) subjects, respectively. On day 28, after the last TM-α administration available for an antibody test, only one patient was positive for anti-TM-α antibodies (0.11%).

CONCLUSION: Our results suggest that TM-α is most effective for treating patients with sepsis-induced DIC when administered within the first 3 days after diagnosis.

Keywords: Anticoagulant; JAAM criteria; SIRS; SOFA score; Sepsis

References

  1. Crit Care. 2011;15(3):R123 - PubMed
  2. Crit Care Med. 2008 Jan;36(1):296-327 - PubMed
  3. JAMA. 2001 Oct 17;286(15):1869-78 - PubMed
  4. Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1825-30 - PubMed
  5. Thromb Res. 2009 Mar;123(5):715-8 - PubMed
  6. J Thromb Haemost. 2007 Jan;5(1):31-41 - PubMed
  7. Intensive Care Med. 2013 Apr;39(4):644-52 - PubMed
  8. Blood. 2007 Apr 15;109(8):3161-72 - PubMed
  9. Br J Haematol. 2005 Nov;131(4):417-30 - PubMed
  10. Crit Care Med. 2006 Mar;34(3):625-31 - PubMed
  11. N Engl J Med. 2001 Mar 8;344(10 ):699-709 - PubMed
  12. Respir Care. 2010 Jul;55(7):901-10 - PubMed
  13. Shock. 2011 Apr;35(4):349-54 - PubMed
  14. Crit Care Med. 2007 Sep;35(9):2191-5 - PubMed
  15. Crit Care Med. 1992 Jun;20(6):864-74 - PubMed
  16. Crit Care Med. 2013 Sep;41(9):2069-79 - PubMed
  17. Thromb J. 2013 Feb 18;11(1):3 - PubMed
  18. JAMA. 2001 Oct 10;286(14):1754-8 - PubMed
  19. J Thromb Haemost. 2011 Jul;9 Suppl 1:168-73 - PubMed
  20. Blood. 2008 Nov 1;112(9):3661-70 - PubMed
  21. Thromb Res. 2013 May;131(5):436-43 - PubMed

Publication Types